Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Clarithromycin Clear all
Completed Phase 1 Interventional

An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.

NCT00002194
View directory record Official record
Conditions
HIV Infections
Interventions
Erythromycin, Nevirapine, Clarithromycin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

NCT01559935
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 3 Interventional

Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis

NCT00644553
View directory record Official record
Conditions
Acute Bacterial Sinusitis (ABS)
Interventions
Clarithromycin, Amoxicillin
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Clovis, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 18, 2026, 7:00 AM EDT
Recruiting Phase 4 Interventional

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

NCT06396078
View directory record Official record
Conditions
Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth
Interventions
Ceftriaxone 1000 MG, Clarithromycin 500mg, Metronidazole 500 mg, Ampicillin 2 GM Injection, Amoxicillin 250 MG, Azithromycin, Erythromycin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01159574
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, clarithromycin, Pomalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

NCT03440112
View directory record Official record
Conditions
Parkinson Disease
Interventions
Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020)
Drug
Lead sponsor
Nicolaas Bohnen, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients

NCT00001023
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin, Azithromycin, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
11
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

NCT00774696
View directory record Official record
Conditions
Healthy
Interventions
clarithromycin 500mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 4 Interventional Results available

High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population

NCT05342532
View directory record Official record
Conditions
Helicobacter Pylori Infection
Interventions
Amoxicillin, Omeprazole, Clarithromycin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions

NCT00602498
View directory record Official record
Conditions
Infection
Interventions
Clarithromycin
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 2 Interventional

Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

NCT00001039
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
8
States / cities
Tucson, Arizona • Baltimore, Maryland • Camden, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Clarithromycin on LY2216684

NCT01460407
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Clarithromycin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 18, 2026, 7:00 AM EDT
Not yet recruiting Phase 3 Interventional

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans

NCT07104318
View directory record Official record
Conditions
Helicobacter Pylori
Interventions
Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 2 Interventional

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

NCT00182663
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
clarithromycin, thalidomide, dexamethasone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 18, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional Results available

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

NCT01374217
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tadalafil, Lenalidomide, Dexamethasone, Clarithromycin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 18, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

NCT04843579
View directory record Official record
Conditions
Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
Interventions
Selinexor, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 74 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1

NCT07224035
View directory record Official record
Conditions
H Pylori Infection, H Pylori Gastritis, Gastric Cancer
Interventions
PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT00538733
View directory record Official record
Conditions
Multiple Myeloma
Interventions
thalomid, lenalidomide, clarithromycin, dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 2 Interventional

A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS

NCT00000644
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

NCT01454076
View directory record Official record
Conditions
Nonhematologic Malignancies, Lymphoma
Interventions
Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

NCT00318708
View directory record Official record
Conditions
Asthma
Interventions
clarithromycin, fluticasone propionate, placebo clarithromycin
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 18, 2026, 7:00 AM EDT
Terminated Phase 1 Interventional

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

NCT03043989
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Cabazitaxel, Clarithromycin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 18, 2026, 7:00 AM EDT
Completed Not applicable Interventional

Sleep/Wake State Assessment with Non-invasive Earbuds

NCT05066009
View directory record Official record
Conditions
Hypersomnolence
Interventions
NextSense EEG-enabled earbuds, Ellcie Healthy eyeglasses, Drug Holiday
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 18, 2026, 7:00 AM EDT